Want to see AU:IMU full AI Analyst Report?

Imugene (IMU) Price & Analysis

151 Followers

IMU Stock Chart & Stats

AU$0.07

AU$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

AU$0.07

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.46

Previous CloseN/A

Volume4.23M

Average Volume (3M)2.19M

Market Cap

AU$25.80M

Enterprise ValueAU$43.81

Total Cash (Recent Filing)AU$2.63M

Total Debt (Recent Filing)AU$6.30M

Price to Earnings (P/E)―

Beta2.42

Next Earnings

Mar 03, 2027

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding548,901,500

10 Day Avg. Volume3,217,565

30 Day Avg. Volume2,190,026

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.16

Price to Sales (P/S)0.00

P/FCF Ratio-0.84

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.08

Revenue Forecast (FY)AU$1.67M

Bulls Say, Bears Say

Bulls Say

Relatively Low LeverageRelatively low leverage gives Imugene some balance-sheet flexibility compared with a highly debt-funded biotech. Modest debt can reduce fixed financial obligations and refinancing pressure, although the benefit is tempered by falling equity and assets and does not remove funding risk.

Immuno-oncology PipelineImugene’s focus on novel cancer immunotherapies and a pipeline spanning preclinical and clinical candidates provides multiple potential development paths. This platform orientation can support long-term value creation if programs advance, though candidates remain development-stage rather than commercial products.

Improved Free Cash Flow In 2025Free cash flow improved in 2025 versus 2024, indicating some year-to-year variability rather than an uninterrupted deterioration. However, 2026 still showed large outflows, so this is only a limited operational positive and does not establish self-funding capacity.

Bears Say

No Dependable Commercial Revenue BaseRevenue contraction, including zero revenue in the 2026 annual period, shows that the company has not established a dependable commercial sales base. Without recurring product revenue, ongoing research and corporate costs remain dependent on financing or future partnering rather than internally generated funds.

Persistent Operating LossesPersistent, sizable EBIT and net losses across the reported periods indicate that operating expenses materially exceed the company’s revenue base. Continued unprofitability limits internally funded investment and makes successful clinical progress and future financing important to sustaining operations.

Balance-sheet ErosionSharp declines in stockholders’ equity and total assets indicate capital erosion consistent with ongoing cash burn. A smaller equity cushion reduces resilience during continued losses, increases reliance on external capital, and can raise dilution or financing risk if funding conditions become less favorable.

Imugene News

Imugene Seeks ASX Quotation for 15.8 Million New Shares

Imugene ( ($AU:IMU) ) has shared an update. Imugene Limited has applied for quotation of 15,813,253 new ordinary...

12d ago

Imugene Issues 43.4 Million New Shares Under Capital Raising

Imugene ( ($AU:IMU) ) has provided an update. Imugene Limited has issued 43,368,423 fully paid ordinary shares at...

19d ago

Imugene seeks ASX quotation for 15.8 million new shares

An announcement from Imugene ( ($AU:IMU) ) is now available. Imugene Limited has applied to the ASX for...

19d ago

Imugene Director’s Options Lapse Without Exercise

Imugene ( ($AU:IMU) ) has shared an announcement. Imugene Limited has disclosed a change in the interests of...

19d ago

Imugene Posts Wider Loss and Sharp Fall in Net Tangible Assets

An announcement from Imugene ( ($AU:IMU) ) is now available. Imugene Limited reported audited results for the year...

23d ago

Imugene Restructures Convertible Notes and Raises Capital to Back Cancer Trials

An update from Imugene ( ($AU:IMU) ) is now available. Imugene has entered into an amended subscription agreement...

24d ago

Imugene Issues New Warrants and Convertible Notes to Bolster Funding

An update from Imugene ( ($AU:IMU) ) is now available. Imugene Limited has notified the market of the...

25d ago

Imugene Cancels 4,200 Convertible Notes Under Capital Management Move

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited has reported the cessation of 4,200 convertible notes,...

25d ago

Imugene Seeks ASX Quotation for 27.6 Million New Shares

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited has applied for quotation of 27,578,949 ordinary fully...

26d ago

Imugene Restructures Convertible Notes to Boost Financial Flexibility

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited has renegotiated the terms of its existing convertible...

1M ago

IMU FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is AU$25.80M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Mar 03, 2027 which is in 164 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Sep 02, 2026. The company reported -AU$0.03 earnings per share for the quarter, beating the consensus estimate of -AU$0.036 by AU$0.006.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate is -0.05.

How many shares outstanding does Imugene have?

Imugene has 548,901,500 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -AU$0.03 in its last earnings report, beating expectations of -AU$0.036. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in AU:IMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-70.87%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.